AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6366560
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Symptomatic treatment only)
Trial: 24485080
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of gel of lidocaine 2% intrarectal with 50mg tramadol (2 tablets)
Trial: 24485080
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of lidocaine 2% injected at the level of periprostatics laterals and apical areas
Trial: 22791802
Drug: Saline-based tetrastarch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline-based tetrastarch HES infusion
Trial: 22791802
Drug: Balanced solution-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced solution-based HES infusion
Trial: 18060924
Drug: Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Therapy Group
Trial: 15943224
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg genistein
Trial: 15943224
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg genistein
Trial: 15943224
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg genistein
Trial: 15943224
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg genistein
Trial: 10435880
Drug: Pirenzepine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (100 mg p.o.) before GHRH injection
Trial: 838992
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aerosol (BDA), 50 mug four times daily
Trial: 25305230
Drug: Prophylactic cloxacillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic cloxacillin (2 g IV) or clindamycin (600 mg IV)
Trial: 21267804
Drug: Piperacillin/tazobactam 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam 4.5 g i.v. (single-dose)
Trial: 21267804
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg or cotrimoxazol 960 mg i.v./p.o. (5 days)
Trial: 21267804
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (varied administration and duration of different antibiotics)
Trial: 19799843
Drug: Alum-adjuvanted whole-virus
RxNorm normalized name: alum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alum-adjuvanted whole-virus vaccine (45 microg)
Trial: 19799843
Drug: Alum-adjuvanted whole-virus
RxNorm normalized name: alum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alum-adjuvanted whole-virus vaccine (15 microg)
Trial: 19799843
Drug: Alum-adjuvanted whole-virus
RxNorm normalized name: alum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alum-adjuvanted whole-virus vaccine (5 microg)
Trial: 19799843
Drug: Intradermal whole-virus
RxNorm normalized name: INFLUENZA A VIRUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal whole-virus vaccine
Trial: 14728939
Drug: Rectal bleeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal bleeding with altered bowel habit
Trial: 14728939
Drug: Isolated rectal
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated rectal bleeding
Trial: 11297722
Drug: Fluoxetine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (n = 16)
Trial: 9106123
Drug: Selegiline (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (20 mg daily)
Trial: 3794874
Drug: Single-dose gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose gentamicin therapy
Trial: 3794874
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment for 10 days
Trial: 22502816
Drug: Intermittent androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent androgen deprivation therapy (ADT)
Trial: 22502816
Drug: Continuous androgen
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous androgen deprivation therapy (ADT)
Trial: 15899109
Drug: Palonosetron 0.25mg
RxNorm normalized name: FOSNETUPITANT 235/PALONOSETRON 0.25MG/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.25mg IV with aprepitant 125 mg on day 1 and 80 mg on days 2 and 3
Trial: 12559781
Drug: Structured antiviral
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured antiviral drug treatment interruptions (STIs) with therapeutic HIV immunizations
Trial: 12559781
Drug: Structured antiviral
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured antiviral drug treatment interruptions (STIs) without therapeutic HIV immunizations
Trial: 1659189
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine (ddI) administered orally twice daily at a total daily dose of 750 mg or 1,500 mg for 12 weeks
Trial: 6992834
Drug: Aromatic retinoid
RxNorm normalized name: Curcuma aromatica root oil
DrugBank: Curcuma aromatica root oil (DB11301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatic retinoid (Ro 10‐9359) orally (0.50‐0.66 mg/kg body weight) and placebo cream topically
Trial: 6992834
Drug: Aromatic retinoid
RxNorm normalized name: Curcuma aromatica root oil
DrugBank: Curcuma aromatica root oil (DB11301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatic retinoid (Ro 10‐9359) orally (0.50‐0.66 mg/kg body weight) with 0.1% triamcinolone acetonide and 5% salicylic acid in lanette wax cream
Trial: 6992834
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules with 0.1% triamcinolone acetonide and 5% salicylic acid in lanette wax cream
Trial: 30745183
Drug: Psychoeducational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational therapy
Trial: 23499440
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks (cohort A)
Trial: 23499440
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg plus peginterferon and ribavirin for 24 weeks (cohort B)
Trial: 23499440
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of sofosbuvir plus peginterferon and ribavirin followed by 12 weeks of either sofosbuvir monotherapy or sofosbuvir plus ribavirin (cohort C)
Trial: 16758944
Drug: HHD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HHD with 6% hydroxyethyl starch (HES) 130/0.4 solution, 15 ml/kg before anesthesia and 33 ml/kg intraoperatively
Trial: 26951208
Drug: Edoxaban, with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban, with a 50% dose reduction in patients with low body weight (≤60 kg), moderate renal impairment (CLCR ≤50 mL/min), or concomitant P-glycoprotein inhibitors.
Trial: 26951208
Drug: Edoxaban without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban without specified dose reduction.
Trial: 22574572
Drug: Variable-frequency electroacupuncture
RxNorm normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable-frequency electroacupuncture (EA) combined with herbal-moxa moxibustion (15 cm roll, components include corydalis tuber, astragali radix, myrrh, etc.), applied to Jiaji (EX-B 2) and Ashi-point, once daily for 7 days.
Trial: 22574572
Drug: Brufen (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brufen (0.3 g, b.i.d.), vitamin B1 (10 mg, t.i.d.), vitamin E (100 mg, b.i.d.)
Trial: 22574572
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received treatment and assessed using the visual analog scale (VAS) for pain reaction.
Trial: 19661237
Drug: Flexible VA-guided
RxNorm normalized name: VP/VA COPOLYMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible VA-guided regimen after three initial injections of ranibizumab
Trial: 19661237
Drug: Monthly and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly and quarterly VA-guided regimens
Trial: 15262458
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg/d with diet (S-D)
Trial: 9151289
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g of acetaminophen (oral dose)
Trial: 3304479
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) alone for 4 months followed by chemotherapy + TAM
Trial: 3304479
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) + chemotherapy simultaneously
Trial: 3304479
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone for 8 months followed by TAM + chemotherapy
Trial: 15256232
Drug: Keeping the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keeping the drain in until discharge had decreased to less than 40 ml/24 h
Trial: 9362160
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (hydroxyurea or busulfan)
Trial: 3320229
Drug: Both anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both anesthetic agents
Trial: 28834259
Drug: Golimumab (tumor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab (tumor necrosis factor inhibitor), dosage not specified, duration 24 weeks
Trial: 26291335
Drug: Vilazodone (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilazodone (20-40 mg/day)
Trial: 21188521
Drug: Vitamin K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K1 (oral daily dose)
Trial: 21188521
Drug: Vitamin K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K1 (intravenous weekly doses)
Trial: 10901114
Drug: n-butyl acetate
RxNorm normalized name: n-butyl acrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-butyl acetate at 12 ppm (44 or 56 mg/m3)
Trial: 10901114
Drug: n-butyl acetate
RxNorm normalized name: n-butyl acrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-butyl acetate at 48 ppm (180 or 228 mg/m3)
Trial: 10901114
Drug: toluene at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: toluene at 12 ppm (44 or 56 mg/m3)
Trial: 10901114
Drug: toluene at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: toluene at 48 ppm (180 or 228 mg/m3)
Trial: 8929726
Drug: DTPw-HB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPw-HB vaccine administered according to a 0, 1.5, 3-month schedule
Trial: 26205801
Drug: Intravenous Desferrioxamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Desferrioxamine, 40 mg/kg/day, 6 days per week for 6 months
Trial: 26205801
Drug: Subcutaneous Desferrioxamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Desferrioxamine, 40 mg/kg/day, 6 days per week 8-12 hours per day for 6 months
Trial: 26205801
Drug: Oral Deferiprone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Deferiprone, 75 mg/kg/day in three divided doses daily for 6 months
Trial: 26205801
Drug: Oral Deferasirox,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Deferasirox, 30 mg/kg/day in single dose on empty stomach daily for 6 months
Trial: 19741188
Drug: high-carbohydrate/high-fiber diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-carbohydrate/high-fiber diet (52% total energy, 28 g/1,000 kcal fiber, low glycemic index 58%)
Trial: 17121134
Drug: Continuous MgSO4
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous MgSO4 infusion (12 grams in 500 ml normal saline daily for 12 days)
Trial: 17121134
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no MgSO4 infusion)
Trial: 11329798
Drug: Verteporfin (Visudyne)
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin (Visudyne) used in conjunction with laser activation (photodynamic therapy) for AMD treatment
Trial: 9158305
Drug: PGE2 gel
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 gel (Prepidil) 0.5 mg in 2.5 ml of triacetin gel
Trial: 7962672
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg nimodipine orally
Trial: 7962672
Drug: 2.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/kg tirilazad mesylate as a 10‐minute intravenous infusion
Trial: 7962672
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nimodipine and tirilazad mesylate
Trial: 3609067
Drug: Oral dose
RxNorm normalized name: Exactamed Oral Dose Syringe 35cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of 10 mg dihydroergosine
Trial: 3609067
Drug: Intravenous dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dose of 0.75 mg dihydroergosine
Trial: 29415825
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (1 g daily)
Trial: 29415825
Drug: Metformin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1 g daily)
Trial: 29415825
Drug: Control (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (1 g cellulose daily)
Trial: 26171380
Drug: Morning aerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning aerobic exercises and medicine
Trial: 26171380
Drug: Afternoon aerobic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Afternoon aerobic exercises and medicine
Trial: 21812891
Drug: PF-04603629 (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04603629 (70 mg)
Trial: 12052991
Drug: Intra-arterial recombinant
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial recombinant prourokinase plus intravenous heparin
Trial: 12052991
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin only
Trial: 8520194
Drug: IVF with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVF with sperm stimulants (PF alone or PF + 2DA)
Trial: 2266066
Drug: Aminophylline injection
RxNorm normalized name: aminophylline Injection
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline injection in patients with mild spontaneous attacks
Trial: 192560
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg trimeprazine
Trial: 192560
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg trimeprazine
Trial: 192560
Drug: Withdrawal after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal after 10 mg and 20 mg
Trial: 29282267
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and exercise programme for 18 weeks, followed by cognitive behavioural therapy, knee brace, or muscle strengthening for 12 weeks if remission is not achieved
Trial: 25782319
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with amlodipine and ramipril
Trial: 19888560
Drug: Olanzapine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (7.5 mg) plus mifepristone (600 mg)
Trial: 19888560
Drug: Olanzapine plus
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine plus mifepristone (600 mg)
Trial: 17568325
Drug: N-acetylcysteine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (150 mg/kg loading dose; 15 mg/kg/hr continuous infusion)
Trial: 8085933
Drug: Daily home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily home exercise program aimed at stretching the hamstrings for 4 weeks
Trial: 23002126
Drug: Docetaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (100 mg/m² day 1 q3W)
Trial: 23002126
Drug: Vinorelbine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (25 mg/m² day 1 q2W)
Trial: 18171294
Drug: Combined ART
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined ART and IL-2 therapy
Trial: 10764713
Drug: Loxiglumide (CCK-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (CCK-A receptor antagonist) with long chain fatty acids
Trial: 8612393
Drug: 0.45 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 mg/kg methylnaltrexone plus 0.05 mg/kg morphine
Trial: 8612393
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg morphine
Trial: 8612393
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus 0.05 mg/kg morphine
Trial: 3881608
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (discontinued medication without dietary intervention)
Trial: 29229466
Drug: Intravenous electrocoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous electrocoagulation (EC)
Trial: 27394382
Drug: High vegetable
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High vegetable and fiber, low-fat diet with daily physical activity goals
Trial: 16722866
Drug: Topical antifungal
RxNorm normalized name: Imidazole and triazole derivatives, topical antifungals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antifungal nail lacquer (ciclopirox 8%)
Trial: 12848775
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg x m(‐2) with zosuquidar 3HCl
Trial: 12848775
Drug: Paclitaxel 225
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 225 mg x m(‐2) with zosuquidar 3HCl
Trial: 12848775
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg x m(‐2) alone
Trial: 10535716
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) administered at home (0.1 mL per kg body weight subcutaneously twice daily)
Trial: 10535716
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin administered in hospital
Trial: 10535716
Drug: Subcutaneous calcium
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous calcium heparin (SCHep) administered at home (0.5 mL bid)
Trial: 10535716
Drug: Subcutaneous calcium
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous calcium heparin (SCHep)
Trial: 8559429
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IgIV) treatment
Trial: 14699594
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange (PE) treatment
Trial: 6840181
Drug: Intravenous melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous melphalan (10 mg)
Trial: 6840181
Drug: Oral melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral melphalan (10 mg)
Trial: 29652273
Drug: Milrinone infusion
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone infusion 0.5 μg/kg/min without a loading dose followed by 0.5‐0.75 μg/kg/min
Trial: 29652273
Drug: Milrinone infusion
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone infusion with loading dose 50 μg/kg over 10 min followed by 0.5‐0.75 μg/kg/min
Trial: 27338218
Drug: 150% portion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150% portion of milk (275 g)
Trial: 22045830
Drug: Ibutilide 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide 1 mg intravenously
Trial: 16926775
Drug: saquinavir SGC/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saquinavir SGC/ritonavir (1600 mg/100 mg)
Trial: 16926775
Drug: efavirenz (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz (600 mg)